SEC jumps in­to the Fi­bro­Gen fi­as­co with a sub­poe­na, prob­ing car­dio da­ta ma­nip­u­la­tion

As­traZeneca part­ner Fi­bro­Gen stunned an­a­lysts last April with the news that the safe­ty da­ta around their ane­mia drug rox­adu­s­tat had been doc­tored up to make …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER